Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Priority Health has launched PriorityGPS™, an integrated health navigation and advocacy solution, through a partnership with Accolade (Nasdaq: ACCD). This product targets self-funded large employers, aiming to simplify employee access to benefits. PriorityGPS offers a single point of contact for support, including appointment scheduling and coverage guidance. The collaboration enhances personalized healthcare and is designed to improve employee engagement while lowering costs. Priority Health continues to prioritize quality care for its members.
Accolade, Inc. (NASDAQ: ACCD) reported a strong fiscal first quarter 2023, achieving revenue of $85.5 million, a 44% increase from $59.5 million in the same quarter last year. Despite a significant net loss of $342.8 million due to a goodwill impairment charge, adjusted gross profit rose 63% to $39.0 million, with an adjusted gross margin of 45.6%. The company raised its revenue guidance midpoint, reflecting confidence in its business model and market demand for personalized healthcare solutions amidst ongoing challenges in the healthcare system.
Accolade (Nasdaq: ACCD) will showcase its Personalized Healthcare solutions at AHIP 2022 from June 21-23 in Las Vegas. The company aims to meet the needs of health plans seeking virtual-first care options. Key presentations include Dr. Shantanu Nundy discussing a post-pandemic framework for chronic care and Dr. Anupam Goel addressing virtual care for chronic diseases. Accolade emphasizes its partnership with Priority Health to enhance member engagement and satisfaction in Michigan by integrating virtual and in-person healthcare services.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q1 2023 financial results on June 30, 2022, after market close. A conference call is scheduled for 4:30 p.m. E.T. the same day to discuss the results. This healthcare provider serves over 600 employers, delivering personal and value-based healthcare solutions to millions of members. Accolade's services include virtual primary care and mental health support, consistently achieving consumer satisfaction ratings over 90%. For more details, visit ir.accolade.com.
Accolade, Inc. (NASDAQ: ACCD) has announced its participation in several upcoming investor conferences. The events include:
- June 8: Stifel 2022 Cross Sector Insight Conference at 4:10 pm ET in Boston
- June 9: 42nd Annual William Blair Growth Stock Conference at 3:00 pm ET in Chicago
- June 16: Goldman Sachs 43rd Annual Global Healthcare Conference at 12:20 pm ET in Rancho Palos Verdes, CA
Details and webcasts from these conferences will be available at ir.accolade.com.
Accolade, Inc. (NASDAQ: ACCD) announced its participation in two upcoming investor conferences. The first is on May 12 at 1pm ET at the BofA Securities 2022 Healthcare Conference in Las Vegas, and the second is on May 16 at 9:30am ET at the virtual 17th Annual Needham Technology & Media Conference. Accolade aims to enhance healthcare experiences through personalized, data-driven solutions, boasting consumer satisfaction ratings exceeding 90%. Webcasts will be available at ir.accolade.com for those interested.
Accolade (Nasdaq: ACCD) has launched Medication Integrated Care, a new solution aimed at helping employers tackle rising prescription drug costs and complications in medication management. With employer health plan costs climbing sharply, particularly a 7.4% increase in prescription drug spending in 2021, this service combines pharmacist-led medication therapy management with advanced analytics from Rx Savings Solutions. By identifying high-risk members, Medication Integrated Care aims to reduce both out-of-pocket expenses and hospital admissions, ultimately improving the overall healthcare experience for employees.
Accolade (Nasdaq: ACCD) appointed Jennifer Hanson as Chief Human Resources Officer and Executive Vice President of People and Culture as of May 2, 2022. She will oversee employee experience across eight global offices, enhancing engagement and professional growth. With over 20 years in healthcare HR, Hanson aims to attract and retain top talent in a growing employer healthcare market. CEO Rajeev Singh highlighted her innovation experience as vital for fostering a strong workplace culture amidst a transformative period for healthcare.
Accolade, Inc. (NASDAQ: ACCD) reported a 58% increase in fiscal Q4 2022 revenue, reaching $93.8 million compared to $59.2 million in Q4 2021. For the full fiscal year, revenue grew 82% to $310 million, up from $170.4 million. Despite strong growth, Accolade is moderating its top-line growth objectives due to a large client terminating its service relationship. The company reported a net loss of $34.6 million for Q4 and $123.1 million for the year. However, Cash reserves stand at $366 million, supporting future growth.
Accolade, Inc. (NASDAQ: ACCD) announced it will release its fiscal fourth quarter and full year 2022 financial results on April 28, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. for detailed results discussion. Accolade is a healthcare provider serving over 600 employers and millions of members, focusing on personalized healthcare experiences. The company combines virtual primary care and intelligent technology to improve health outcomes and consumer satisfaction, maintaining ratings over 90%.